The molecular basis of OX40 on CD4 T cells
The molecular basis of OX40 on CD4 T cells
批准号:
7316167
负责人:
Michael Croft
金额:
$42.53万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-12-01 至 2012-11-30
关键词:
70-kDa Ribosomal Protein S6 KinasesAntigensApoptosisApoptoticBindingCD28 AntigensCD28 geneCD4 Positive T LymphocytesCell Cycle ProgressionCell Differentiation processCell Surface ReceptorsCell SurvivalCell divisionCell membraneCell physiologyCellsClonal ExpansionComplementComplexDataDepthDisease modelEnvironmentEventFamilyFundingGenetic TranscriptionHourImmunizationIn VitroInflammationInflammatoryInterleukin-4Knockout MiceLifeLigandsLigationLocalizedLung InflammationMembraneMembrane MicrodomainsModelingMolecularNuclearNumbersOperative Surgical ProceduresPDPK1 genePathway interactionsPhasePhenotypePhosphorylationPhysiologicalProteinsProviderRaptorsReagentRecruitment ActivityRegulationResearch PersonnelSignal PathwaySignal TransductionSignaling MoleculeSystemT-LymphocyteTNFSF4 geneTestingTransgenic OrganismsTumor Necrosis Factor Receptoraurora B kinasebasecell mediated immune responseconceptcytokinedayhuman FRAP1 proteinin vivoin vivo Modelmembernovelprogramsreceptorresponsesurvivintumortumor necrosis factor ligand superfamily member 4upstream kinase
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): T cell responses are controlled by intracellular signals emanating from ligation of cell surface receptors. While the concept of a second signal has been established for many years, with CD28 representing the initial provider of this second signal, it is clear that signals from several other co-stimulatory receptors are needed for an effective and persistent T cell response. We have extensively studied a member of the TNFR family, namely OX40 (CD134), whose expression is induced on T cells several hours to days after the initial antigen recognition event. We have demonstrated that 0X40 costimulation prolongs clonal expansion of CD4 and CDS T cells by regulating cell cycle progression; enhances T cell differentiation and cytokine secretion particularly toward the Th2 phenotype; and furthermore promotes T cell survival by antagonizing apoptosis. Multiple in vivo studies in varying models of disease over the past 5 or more years have reinforced these conclusions and led to the concept that the synergistic and temporal activities of CD28 and OX40 represent key events in most T cell mediated immune responses. In this renewal application, we seek to extend our functional data and further define molecularly the mode of action of OX40 and how OX40 signals integrate with antigen and CD28 signals. We have shown several common intracellular targets of OX40 including novel molecules survivin and aurora B kinase that regulate G1-S cell cycle progression, and Bcl-2, Bcl-xL, and Bfl-1 that control survival during and after the phase of T cell division. We have developed highly physiological and novel transgenic and retroviral systems to understand regulation of OX40 in primary T cells. We will investigate how OX40 leads to activation of Akt and NF-KB and the extent that these signaling moieties co-operate in promoting cell division and survival of T cells. Specifically, we will determine whether OX40 utilizes PKC0, PDK1, and MEK1/ERK to target Akt and NF-KB, and how these signaling cascades impact the expression and function of survivin and aurora B kinase in regulating division, and the Bcl-2 anti-apoptotic molecules in regulating survival. We will further define how OX40 targets NFATd nuclear accumulation leading to IL-4 secretion and Th2 differentiation, and then define signaling complexes induced by OX40 at the T cell membrane in lipid rafts. Lastly, we will use several models of in vivo T cell response involving lung inflammation and anti-tumor activity to extend the in vitro signaling analyses and understand molecularly how co-stimulatory signaling impacts physiological T cell function. These studies are tremendously important in defining the action of OX40 and the integration of co-stimulatory signals, and in understanding which molecular pathways are necessary and sufficient for promoting a long-lived T cell response.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TWEAK and Skin Inflammation
-
批准号:10400699
-
项目类别:
-
资助金额:$39.2万
-
财政年份:2018
-
负责人:Michael Croft
-
依托单位:
A Treg cell-intrinsic CTLA4-PKC-eta signaling pathway mediating contact-dependent suppression of tumor immunity: A novel target for cancer immunotherapy
-
批准号:10531229
-
项目类别:
-
资助金额:$51.26万
-
财政年份:2018
-
负责人:Michael Croft
-
依托单位:
Immune Regulation by Deubiquitination
-
批准号:9982199
-
项目类别:
-
资助金额:$45.0万
-
财政年份:2018
-
负责人:Michael Croft
-
依托单位:
A Treg cell-intrinsic CTLA4-PKC-eta signaling pathway mediating contact-dependent suppression of tumor immunity: A novel target for cancer immunotherapy
-
批准号:10053328
-
项目类别:
-
资助金额:$52.31万
-
财政年份:2018
-
负责人:Michael Croft
-
依托单位:
TWEAK and Skin Inflammation
-
批准号:9910059
-
项目类别:
-
资助金额:$39.6万
-
财政年份:2018
-
负责人:Michael Croft
-
依托单位:
A Treg cell-intrinsic CTLA4-PKC-eta signaling pathway mediating contact-dependent suppression of tumor immunity: A novel target for cancer immunotherapy
-
批准号:10310411
-
项目类别:
-
资助金额:$51.26万
-
财政年份:2018
-
负责人:Michael Croft
-
依托单位:
TWEAK and Skin Inflammation
-
批准号:10152528
-
项目类别:
-
资助金额:$38.41万
-
财政年份:2018
-
负责人:Michael Croft
-
依托单位:
Immune Regulation by Deubiquitination
-
批准号:9788250
-
项目类别:
-
资助金额:$45.0万
-
财政年份:2018
-
负责人:Michael Croft
-
依托单位:
Training in Immunological Mechanisms
-
批准号:9321444
-
项目类别:
-
资助金额:$33.47万
-
财政年份:2016
-
负责人:Michael Croft
-
依托单位:
Training in Immunological Mechanisms
-
批准号:10675443
-
项目类别:
-
资助金额:$25.73万
-
财政年份:2016
-
负责人:Michael Croft
-
依托单位:
Training in Immunological Mechanisms
-
批准号:10269804
-
项目类别:
-
资助金额:$37.53万
-
财政年份:2016
-
负责人:Michael Croft
-
依托单位:
Training in Immunological Mechanisms
-
批准号:10458735
-
项目类别:
-
资助金额:$33.27万
-
财政年份:2016
-
负责人:Michael Croft
-
依托单位:
Novel PTPRD interaction Controlling T cell Responsiveness
-
批准号:9077779
-
项目类别:
-
资助金额:$26.55万
-
财政年份:2016
-
负责人:Michael Croft
-
依托单位:
Structural Characterization of 4-1BB-Galectin-9 Complexes
-
批准号:8679808
-
项目类别:
-
资助金额:$8.85万
-
财政年份:2014
-
负责人:Michael Croft
-
依托单位:
Control of Airway Tolerance
-
批准号:8577804
-
项目类别:
-
资助金额:$41.6万
-
财政年份:2013
-
负责人:Michael Croft
-
依托单位:
Control of Airway Tolerance
-
批准号:8661698
-
项目类别:
-
资助金额:$44.25万
-
财政年份:2013
-
负责人:Michael Croft
-
依托单位:
Control of Airway Tolerance
-
批准号:9267076
-
项目类别:
-
资助金额:$44.25万
-
财政年份:2013
-
负责人:Michael Croft
-
依托单位:
Novel costimulatory pathways required for T cell regulation
-
批准号:8495230
-
项目类别:
-
资助金额:$43.81万
-
财政年份:2013
-
负责人:Michael Croft
-
依托单位:
Control of Airway Tolerance
-
批准号:9054041
-
项目类别:
-
资助金额:$44.25万
-
财政年份:2013
-
负责人:Michael Croft
-
依托单位:
Control of Airway Tolerance
-
批准号:8839196
-
项目类别:
-
资助金额:$44.25万
-
财政年份:2013
-
负责人:Michael Croft
-
依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
-
批准号:2022J011295
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:王亚伟
-
依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
-
批准号:30801055
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:王丽梅
-
依托单位: